Generation Bio Co. GBIO
Institutional shares held
49.5 Million
20.3K
calls
0
puts
Total value of holdings
$136M
$55K
calls
$0
puts
Market Cap
$162M
59,011,200
Shares Out.
Institutional ownership
83.84%
# of Institutions
79
We take great care to ensure that the data presented and summarized in this overview for Generation Bio Co. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GBIO
View all-
Price T Rowe Associates Inc Baltimore, MD8.88MShares$24.3 Million0.0% of portfolio
-
Atlas Venture Life Science Advisors, LLC8.28MShares$22.7 Million4.22% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.86MShares$10.6 Million0.25% of portfolio
-
Black Rock Inc. New York, NY3.05MShares$8.35 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC2.99MShares$8.19 Million0.0% of portfolio
-
Artal Group S.A. Luxembourg, N42.83MShares$7.76 Million0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.57MShares$7.04 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA2.05MShares$5.61 Million0.24% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA1.62MShares$4.45 Million0.33% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M1.25MShares$3.43 Million0.0% of portfolio
Latest Institutional Activity in GBIO
Top Purchases
Top Sells
About GBIO
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at GBIO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 15
2024
|
Yalonda Howze CHIEF LEGAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,930
-29.35%
|
$11,790
$3.7 P/Share
|
|
Apr 15
2024
|
Yalonda Howze CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
13,388
+50.0%
|
-
|
|
Apr 15
2024
|
Geoff Mcdonough PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,548
-0.12%
|
$4,644
$3.7 P/Share
|
|
Apr 15
2024
|
Geoff Mcdonough PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,274
+0.4%
|
-
|
|
Apr 15
2024
|
Matthew Norkunas CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
984
-0.94%
|
$2,952
$3.7 P/Share
|
|
Apr 15
2024
|
Matthew Norkunas CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,347
+3.09%
|
-
|
|
Apr 15
2024
|
Antoinette Paone CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
468
-3.28%
|
$1,404
$3.7 P/Share
|
|
Apr 15
2024
|
Antoinette Paone CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,592
+10.03%
|
-
|
|
Apr 15
2024
|
Phillip Samayoa CHIEF STRATEGY OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
337
-0.3%
|
$1,011
$3.7 P/Share
|
|
Apr 15
2024
|
Phillip Samayoa CHIEF STRATEGY OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,147
+1.0%
|
-
|
|
Apr 15
2024
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
492
-0.2%
|
$1,476
$3.7 P/Share
|
|
Apr 15
2024
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,674
+0.68%
|
-
|
|
Jan 29
2024
|
Douglas Kerr CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,476
-0.38%
|
$1,476
$1.9 P/Share
|
|
Jan 29
2024
|
Douglas Kerr CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,021
+1.28%
|
-
|
|
Jan 29
2024
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,476
-2.91%
|
$1,476
$1.9 P/Share
|
|
Jan 29
2024
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,021
+9.02%
|
-
|
|
Jan 15
2024
|
Antoinette Paone CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,637
-14.59%
|
$3,637
$1.91 P/Share
|
|
Jan 15
2024
|
Antoinette Paone CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,492
+29.63%
|
-
|
|
Jan 15
2024
|
Phillip Samayoa CHIEF STRATEGY OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,020
-1.34%
|
$3,020
$1.91 P/Share
|
|
Jan 15
2024
|
Phillip Samayoa CHIEF STRATEGY OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,712
+3.71%
|
-
|
Last 12 Months Summary
Buy / Acquisition
838K
Shares
From
12
Insiders
| Open market or private purchase | 551K shares |
|---|---|
| Exercise of conversion of derivative security | 286K shares |
Sell / Disposition
106K
Shares
From
10
Insiders
| Payment of exercise price or tax liability | 94.6K shares |
|---|---|
| Open market or private sale | 11.1K shares |